Fig. 6

Inhibition of both EGFR and FGFR signaling significantly delays tumor recurrence. a Survival analysis of tumor regression after single BGJ398 treatment or combined BGJ398 and lapatinib treatment. Six mice in the single BGJ398 treatment group, eight mice in the combined BGJ398 and lapatinib treatment group, 14 mice in total; p = 0.5271. b Survival analysis of tumor recurrence after single BGJ398 treatment or combined BGJ398 and lapatinib treatment. Six mice in the single BGJ398 treatment group, eight mice in the combined BGJ398 and lapatinib treatment group, 14 mice in total; p = 0.0005. c Histological analysis of tumors treated with BGJ398 alone or combined BGJ398 and lapatnib for 10 days. Upper panel: Hematoxylin and eosin (H&E) staining. Lower panel: trichrome staining. d Quantification of percentage of collagen in tumors treated with BGJ398 alone or combined BGJ398 and lapatnib for 10 days; p = 0.0079. e Immunofluorescence double staining of K5 (green) and K8 (red) in tumors treated with BGJ398 alone or combined BGJ398 and lapatnib for 10 days. Nuclear staining is shown in blue (DAPI). f Histological analysis of primary tumors and tumors after single treatment or combined treatment. Upper panel: H&E staining. Lower panel: trichrome staining. g Quantification of percentage of collagen in primary tumors, recurrent tumors from BGJ398 treatment, and recurrent tumors from BGJ398 and lapatinib treatment; ****p < 0.0001. Values are shown as mean ± SEM. h. Immunofluorescence double staining of K5 (red) and K8 (green) in primary tumors and tumors after single treatment or combined treatment. Nuclear staining is shown in blue (DAPI; and subsequent panels). i Immunofluorescence staining of BrdU in primary tumors and tumors after single treatment or combined treatment. j Quantification of BrdU-positive cells in recurrent tumors from combined treatment group (n = 5); ****p < 0.0001. Values are shown as mean ± SEM. k Immunofluorescence staining and quantification of S100A8 (red) in tumors after single treatment or combined treatment; p = 0.0084. l Immunofluorescence staining of α-SMA (red) in tumors after single treatment or combined treatment. α-SMA alpha smooth muscle actin, BGJ BGJ398, BrdU Bromodeoxyuridine, DAPI 4′, 6-Diamidino-2-phenylindole, Lap Lapatinib, Recur Recurrence